I am proud to share my latest article, published @CAonline (an unbelievable impact factor of 508 🤯) We review the tissue-agnostic potential of antibody-drug conjugates The most amazing part is it all started w/ Twitter interactions w/ @PTarantinoMD https://t.co/B9IIJalvRT

#CTOS2025 - a pleasure to moderate the session on Sarcoma & Society: Equity, Quality of Life & Global Care alongside the great Dr. Catherine Sarre and Prof. Winette van de Graaf @sarresurgeon @ctosociety @Winette_vdGraaf

#CTOS2025 - no meeting is complete without a #TrentSelfie! @ctosociety @JTrentMDPhD

Historical - a great win for patients w/ chondrosarcoma! #CTOS2025 @RobinL_Jones

#CTOS2025 - Ozekibart shows impressive benefit in PFS in patients w/ advanced conventional chondrosarcoma. The first randomizes trial w/ benefit of a systemic therapy in this disease @ctosociety @RobinL_Jones

#CTOS2025 - nice to see a presentation highlighting the potential of insights from early-phase trials to treat rare cancers Check our prior publications: https://t.co/TyFgFMPzXc https://t.co/yEleKeKwBG

#CTOS2025 - chondrosarcoma remains hard to treat even in the era of novel agents in the largest phase I unit in the world @MDAndersonNews @ctosociety

#CTOS2025 pathologic fracture associated w/ worse distance metastasis ans disease-specific survival in high-grade chondrosarcoma @ctosociety A product of the biology of these tumors?

#CTOS2025 Following the productive pre-congress meeting on genetic predisposition in sarcoma, a presentation on cancer surveillance for patients with genetic predisposition

Whole lung irradiation (w/ boost when appripriate) shows promising results in adults with Ewing Sarcoma. Unfortunately, still very short PFS for CIC-DUX sarcoma #CTOS2025 @ctosociety

Larotrectinib results in durable responses In patients w/ NTRK fusion-positive swrcomas -12% of patients with responses ongoing after 5 years #CTOS2025 @ctosociety

Molecular profiling is a TOOL for sarcoma diagnosis, morphology is still key. As Prof. Dei Tos states: a fool with a tool is still a fool #CTOS2025 @ctosociety

Herman Suit Lecture by Dr Paolo Dei Tos taking us through the journey of pathologic reclassification of sarcomas: A marriage between pathology and genetics #CTOS2025 #CTOS @ctosociety

Inspiring opening session at #CTOS2025…reminding the past and preparing for a bright future. Especially nice to see GLOBAL collaboration as a goal @ctosociety @SilviaStacchia @alegronchi @DCalleMD @DrCeSarcoma @herbloong #CTOS

30 years' history of @ctosociety elegantly introduced by #SebastianBauer #CTOS2025

Amazing to hear from Dr Bob Benjamin, a sarcoma pioneer, on the history of #CTOS #CTOS2025

#CTOS 2025 started paying respects to the great Dr. Brian Van Tine, who unfortunately left us way too early. Dr. Van Tine was always incredibly kind to me and all in my team and helped my career in many ways

Very honored to be part of this #consensus meeting on germline predispositions in sarcoma! Productive discussions on a very important topic

@TumorBoardTues @pashtoonkasi @IntegrityCE @JulianaRBeal @PestanaRC @camilagismondi_ @CathyEngMD @GIMedOnc @dr_yakupergun @EvelynWongYT @Erman_Akkus @GIcancerDoc @MyriamChalabi @ChiaraCrem1 @TaberneroJosep @ClaraMontagut 🏫 Mini Tweetorial 4 🏫 🔄 Anti-EGFR Rechallenge — WHO? 💧 ctDNA reveals who truly benefits: • Unmasks RAS/BRAF/EGFR-ECD resistance → CITRIC/PARERE: ~⅓ pts excluded by liquid biopsy • @pau_mascaro (ESMO25): low-freq clones don’t blunt ORR/DCR but link to shorter PFS/OS

Interesting #TumorBoardTuesday case discussion on third-line therapy for metastatic pMMR colon cancer. A tough space in which there are many options but still a highly unmet medical need for novel therapies w/ higher and more durable responses.

#tumorboardtuesday ✅Txs4⃣#mCRC have improved significantly - but still many Pts will need additional therapies 📢Join us Tuesday, 10-28-25 at 8PM ET as @pashtoonkasi & @mariaf_teix🗣️3rd-Line Decision-Making in Non-Driver mCRC RT and bring others into the discussion‼️